BioPharm America™ 2012 Press Releases

September 14, 2011Productive partnering, new features showcased at BioPharm America™ 2011 Boston was again the center of life science dealmaking activity as BioPharm America™ 2011 convened Sept 7–9 at the Westin Boston Waterfront Hotel. Nearly 1,000 participants came from 34 countries, represented 588 companies, and engaged in more than 2,500 one-to-one meetings to discuss partnering opportunities and other potential collaborations. "BioPharm America continues to...more ►

August 25, 2011FierceBiotech's 2011 "Fierce 15" winners to be showcased at BioPharm America™ FierceBiotech, the biotech industry's daily monitor, today announced that its 2011 "Fierce 15" winners will be showcased at BioPharm America™, being held at the Westin Boston Waterfront Hotel on September 7–9. The Fierce 15 is the hotly anticipated annual award that recognizes the 15 most promising private biotech companies in the world. "Having FierceBiotech recog...more ►

August 19, 2011Plenary Sessions and Speakers Announced for BioPharm America™ 2011 in Boston EBD Group and MassBio today announced the plenary sessions program for BioPharm America™ 2011, being held at the Westin Boston Waterfront Hotel, September 7–9. After the event's keynote address, top life science executives will lead facilitated panel discussions with audience participation, delivering their insights on crucial issues facing the industry and further enhancing one o...more ►

July 29, 2011BioPharm America™ brings the world's largest pharma companies to Boston Organized by EBD Group, BioPharm America™ 2011, to be held at the Westin Boston Waterfront Hotel September 7–9, is poised to be one of the most productive biotech partnering conferences of the year. The event will play host to the largest pharmaceutical and biotech companies in the world, including Abbott, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Genentech, Gilead, GlaxoSm...more ►

July 7, 2011Shire CEO Angus Russell to Deliver Keynote Address at Fourth Annual BioPharm America™ Partnering Conference EBD Group and MassBio today announced that Angus Russell, CEO of Shire, will be the keynote speaker at BioPharm America™, being held in Boston at the Westin Waterfront, September 7–9, 2011. With more than 1,000 dealmakers expected, the 2011 edition of BioPharm America promises to be one of the most productive partnering events of the year for the biotech industry. "Partnering is...more ►

April 28, 2011EBD Group and MassBio bring BioPharm America™ back to BostonLeading partnering event returns September 7–9, 2011
EBD Group and MassBio today announced a continued collaboration that will bring one of the largest and most productive partnering events in North America back to Boston this fall.  BioPharm America™—which drew more than 900 people to Boston in 2010—will be held September 7–9, 2011 at the Westin Waterfront. BioPharm America continues its growth as the unrivaled...more ►

13 January 2012 Balancing on the innovation high wire The bar is higher than it has ever been for emerging innovators to secure a partnership. Speakers at Tuesday’s plenary luncheon at Biotech Showcase™ 2012 spoke of the realities and substantial challenges of an environment that increasingly incorporates external and internal development programs. more ►

13 January 2012 Lights are flashing green for biotech investment in China While the rest of the world struggles, China is setting new records in venture capital investment, IPO and M&A activity, and partnering deals. more ►

13 January 2012 The exciting state of regenerative medicine Regenerative medicine has the power to transform healthcare, incorporating a wide variety of therapies. When incorporated into clinical practice, regenerative therapies may save USD 250 billion per year in the US alone. more ►

13 January 2012 Biotech investors declare it’s never too early to plan an exit It’s never too early to plan an exit strategy. Panelists at the Biotech Showcase™ 2012 luncheon plenary session Monday all agreed that, although that strategy may include an IPO, exit planning should include other strategies as well. more ►

4 January 2012 Seegene: Multiplex assays key to companion diagnostics The quality of medical treatment is dependent on rapid and accurate diagnosing of the disease, as well as safeguarding the life of the patient. Apart from infectious diseases, most diseases do not have that "tell-all" diagnostic marker that provides an adequate picture of the patient and their particular disease. Seegene, Inc., sees a combination of surrogate markers in a single clinically validated assay as the most effective tool in disease identification, treatment and management, while keeping the patient in focus. more ►